Patient-Derived In Vitro Models for Drug Discovery in Colorectal Carcinoma.
- Ramzy GM Molecular Pharmacology Group, School of Pharmaceutical Sciences, Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, 1211 Geneva, Switzerland.
- Koessler T Department of Oncology, Geneva University Hospitals, 1211 Geneva, Switzerland.
- Ducrey E Molecular Pharmacology Group, School of Pharmaceutical Sciences, Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, 1211 Geneva, Switzerland.
- McKee T Division of Clinical Pathology, Diagnostic Department, University Hospitals of Geneva (HUG), 1211 Geneva, Switzerland.
- Ris F Translational Department of Digestive and Transplant Surgery, Geneva University Hospitals and Faculty of Medicine, 1211 Geneva, Switzerland.
- Buchs N Translational Department of Digestive and Transplant Surgery, Geneva University Hospitals and Faculty of Medicine, 1211 Geneva, Switzerland.
- Rubbia-Brandt L Division of Clinical Pathology, Diagnostic Department, University Hospitals of Geneva (HUG), 1211 Geneva, Switzerland.
- Dietrich PY Department of Oncology, Geneva University Hospitals, 1211 Geneva, Switzerland.
- Nowak-Sliwinska P Molecular Pharmacology Group, School of Pharmaceutical Sciences, Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, 1211 Geneva, Switzerland.
- 2020-06-04
Published in:
- Cancers. - 2020
3D bioprinting
Colorectal cancer
cancer-on-chip
drug combination
organoids
patient-derived xenograft
English
Lack of relevant preclinical models that reliably recapitulate the complexity and heterogeneity of human cancer has slowed down the development and approval of new anti-cancer therapies. Even though two-dimensional in vitro culture models remain widely used, they allow only partial cell-to-cell and cell-to-matrix interactions and therefore do not represent the complex nature of the tumor microenvironment. Therefore, better models reflecting intra-tumor heterogeneity need to be incorporated in the drug screening process to more reliably predict the efficacy of drug candidates. Classic methods of modelling colorectal carcinoma (CRC), while useful for many applications, carry numerous limitations. In this review, we address the recent advances in in vitro CRC model systems, ranging from conventional CRC patient-derived models, such as conditional reprogramming-based cell cultures, to more experimental and state-of-the-art models, such as cancer-on-chip platforms or liquid biopsy.
- Language
-
- English
- Open access status
- gold
- Identifiers
-
- DOI 10.3390/cancers12061423
- PMID 32486365
- Persistent URL
- https://sonar.ch/global/documents/46769
Statistics
Document views: 32
File downloads:
- Full-text: 0